ANIP
HealthcareANI Pharmaceuticals, Inc.
$70.32-2.17 (-3.00%)
Prev Close
$72.49
Open
$72.62
High
$72.90
Low
$70.32
Volume
317.5K
Market Cap
$1.68B
P/E
20.99
Div Yield
—
Over the past 12 months, insider activity at ANI Pharmaceuticals, Inc. (ANIP) has been exclusively selling, with 0 insider purchases totaling $0.00 and 68 insider sales totaling $54.87M. The most recent insider transaction was by Davis Krista (officer: SVP, CHIEF HR OFFICER), who sold $488.5K worth of shares on Mar 10, 2026. ANI Pharmaceuticals, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry, with a market cap of $1.68B.
Buys (12M)
0
$0.00
Sells (12M)
68
$54.87M
Net Activity
Net Seller
$54.87M
Active Insiders
15
last 12 mo
ANIP Price Chart
ANIP Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026↗ | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 6,572 | $74.33 | $488.5K | 57,033 |
| Mar 10, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,723 | $74.19 | $424.6K | 101,387 |
| Mar 5, 2026↗ | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 7,312 | $75.50 | $552.0K | 189,543 |
| Mar 4, 2026↗ | Gutwerg Ori | officer: SVP, GENERICS | Sell | 4,120 | $76.50 | $315.2K | 84,782 |
| Mar 4, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 834 | $74.00 | $61.7K | 103,508 |
| Mar 3, 2026↗ | Walsh Patrick D | director | Sell | 12,000 | $74.23 | $890.8K | 52,405 |
| Feb 23, 2026↗ | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 50,993 |
| Feb 23, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 84,840 |
| Feb 20, 2026↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 0 |
| Feb 19, 2026↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 0 |
| Feb 17, 2026↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,277 | $77.01 | $406.4K | 0 |
| Feb 17, 2026↗ | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $76.80 | $38.4K | 69,329 |
| Feb 17, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 7,032 | $76.55 | $538.3K | 92,566 |
| Feb 12, 2026↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,813 | $77.02 | $293.7K | 0 |
| Feb 12, 2026↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,470 | $77.04 | $190.3K | 0 |
| Feb 12, 2026↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 3,325 | $77.04 | $256.2K | 0 |
| Feb 12, 2026↗ | Gutwerg Ori | SVP, GENERICS | Sell | 3,663 | $77.04 | $282.2K | 0 |
| Feb 12, 2026↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 21,986 | $77.01 | $1.69M | 0 |
| Feb 12, 2026↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 12,608 | $76.74 | $967.6K | 0 |
| Feb 12, 2026↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,051 | $77.00 | $80.9K | 0 |
| Feb 11, 2026↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,503 | $76.25 | $419.6K | 0 |
| Feb 11, 2026↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,011 | $76.25 | $229.6K | 0 |
| Feb 11, 2026↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,017 | $76.25 | $230.0K | 0 |
| Feb 11, 2026↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 4,269 | $76.25 | $325.5K | 0 |
| Feb 11, 2026↗ | Gutwerg Ori | SVP, GENERICS | Sell | 4,267 | $76.25 | $325.4K | 0 |
| Feb 11, 2026↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 30,659 | $76.25 | $2.34M | 0 |
| Feb 11, 2026↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,546 | $76.25 | $346.6K | 0 |
| Feb 11, 2026↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,762 | $76.25 | $134.4K | 0 |
| Feb 11, 2026↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,898 | $76.25 | $221.0K | 0 |
| Jan 14, 2026↗ | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 74,374 |
| Jan 13, 2026↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 0 |
| Dec 18, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,622 | $82.40 | $133.7K | 0 |
| Dec 12, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $82.32 | $32.9K | 0 |
| Dec 5, 2025↗ | TANNENBAUM RENEE P | Director | Sell | 1,800 | $81.15 | $146.1K | 0 |
| Nov 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $87.27 | $34.9K | 0 |
| Nov 13, 2025↗ | Walsh Patrick D | Director | Sell | 8,643 | $86.88 | $750.9K | 0 |
| Nov 12, 2025↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 14,736 | $89.06 | $1.31M | 0 |
| Oct 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $90.09 | $36.0K | 0 |
| Sep 19, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $98.04 | $98.0K | 0 |
| Sep 12, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $98.42 | $39.4K | 0 |
| Sep 12, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,710 | $97.71 | $167.1K | 0 |
| Sep 3, 2025↗ | Pera Antonio R | Director | Sell | 7,292 | $94.94 | $692.3K | 0 |
| Aug 25, 2025↗ | Leonard Matthew J | Director | Sell | 2,528 | $90.62 | $229.1K | 0 |
| Aug 22, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,763 | $91.10 | $160.6K | 0 |
| Aug 20, 2025↗ | Pera Antonio R | Director | Sell | 5,421 | $89.73 | $486.4K | 0 |
| Aug 20, 2025↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 100,000 | $90.36 | $9.04M | 0 |
| Aug 18, 2025↗ | Leonard Matthew J | Director | Sell | 6,937 | $88.17 | $611.6K | 0 |
| Aug 18, 2025↗ | Thoma Jeanne | Director | Sell | 21,540 | $89.15 | $1.92M | 0 |
| Aug 15, 2025↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $86.97 | $1.74M | 0 |
| Aug 15, 2025↗ | Walsh Patrick D | Director | Sell | 9,000 | $89.05 | $801.5K | 0 |
| Aug 14, 2025↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 100,000 | $88.25 | $8.82M | 0 |
| Aug 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $88.87 | $35.5K | 0 |
| Aug 12, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 50,000 | $86.07 | $4.30M | 0 |
| Aug 12, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 5,873 | $86.53 | $508.2K | 0 |
| Aug 12, 2025↗ | HAUGHEY THOMAS | Director | Sell | 19,341 | $85.93 | $1.66M | 0 |
| Aug 12, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 56,960 | $85.93 | $4.89M | 0 |
| Aug 12, 2025↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 4,975 | $85.71 | $426.4K | 0 |
| Jul 18, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 2,071 | $66.30 | $137.3K | 0 |
| Jul 14, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $64.88 | $26.0K | 0 |
| Jun 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $61.37 | $24.5K | 0 |
| May 15, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 881 | $60.07 | $52.9K | 0 |
| May 14, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,000 | $60.45 | $241.8K | 0 |
| May 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $62.20 | $24.9K | 0 |
| May 9, 2025↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 700 | $76.83 | $53.8K | 0 |
| Apr 14, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $68.96 | $27.6K | 0 |
| Mar 23, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 6,210 | $64.26 | $399.1K | 0 |
| Mar 23, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,455 | $64.26 | $1.12M | 0 |
| Mar 19, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,866 | $65.00 | $121.3K | 0 |
| Mar 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $63.33 | $25.3K | 0 |
| Mar 7, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,150 | $60.62 | $312.2K | 0 |
| Mar 7, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $60.86 | $60.9K | 0 |
| Mar 7, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 3,314 | $60.62 | $200.9K | 0 |
| Mar 7, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,060 | $60.62 | $1.03M | 0 |
| Mar 7, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,874 | $60.62 | $174.2K | 0 |
| Mar 5, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 5,384 | $60.00 | $323.0K | 0 |
| Feb 28, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 1,861 | $61.89 | $115.2K | 0 |
| Feb 28, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,099 | $61.89 | $68.0K | 0 |
| Feb 28, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,099 | $61.89 | $68.0K | 0 |
| Feb 28, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,570 | $61.89 | $97.2K | 0 |
| Feb 28, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 12,216 | $61.89 | $756.0K | 0 |
| Feb 28, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,275 | $61.89 | $78.9K | 0 |
| Feb 28, 2025↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 627 | $61.89 | $38.8K | 0 |
| Feb 21, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $60.20 | $60.2K | 0 |
| Feb 12, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 1,730 | $58.92 | $101.9K | 0 |
| Feb 12, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,834 | $59.06 | $108.3K | 0 |
| Feb 12, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,196 | $58.92 | $70.5K | 0 |
| Feb 12, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,593 | $58.92 | $152.8K | 0 |
| Feb 12, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 7,799 | $58.92 | $459.5K | 0 |
| Feb 12, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,657 | $58.92 | $156.6K | 0 |
| Feb 12, 2025↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 582 | $58.92 | $34.3K | 0 |
| Jan 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $53.92 | $21.6K | 0 |
| Dec 17, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 7,500 | $55.79 | $418.4K | 0 |
| Dec 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.24 | $14.1K | 0 |
| Dec 11, 2024↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $60.00 | $60.0K | 0 |
| Nov 26, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 33,481 | $57.99 | $1.94M | 0 |
| Nov 15, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 6,500 | $57.70 | $375.1K | 0 |
| Nov 15, 2024↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 867 | $56.58 | $49.1K | 0 |
| Nov 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $61.36 | $15.3K | 0 |
| Oct 14, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $57.19 | $14.3K | 0 |
| Sep 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.82 | $14.2K | 0 |
| Sep 12, 2024↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,486 | $56.15 | $83.4K | 0 |
| Sep 8, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 3,646 | $60.51 | $220.6K | 0 |
| Aug 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $59.62 | $14.9K | 0 |
| Jul 18, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,743 | $61.35 | $106.9K | 0 |
| Jul 18, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,743 | $62.00 | $170.1K | 0 |
| Jul 15, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 47,257 | $63.73 | $3.01M | 0 |
| Jul 12, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $64.91 | $16.2K | 0 |
| Jul 1, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $63.44 | $1.27M | 0 |
| Jun 21, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 20,000 | $58.90 | $1.18M | 0 |
| Jun 17, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 30,000 | $60.59 | $1.82M | 0 |
| Jun 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $63.80 | $15.9K | 0 |
| Jun 7, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 11,087 | $67.70 | $750.6K | 0 |
| Jun 5, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,985 | $67.00 | $200.0K | 0 |
| Jun 4, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,000 | $63.58 | $317.9K | 0 |
| Jun 3, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $64.41 | $1.29M | 0 |
| May 21, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,000 | $61.61 | $123.2K | 0 |
| May 20, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 12,855 | $61.81 | $794.6K | 0 |
| May 16, 2024↗ | TANNENBAUM RENEE P | Director | Sell | 2,000 | $63.87 | $127.7K | 0 |
| May 15, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 37,145 | $64.37 | $2.39M | 0 |
| May 14, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 16,669 | $66.10 | $1.10M | 0 |
| May 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $67.69 | $16.9K | 0 |
| May 1, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $66.62 | $1.33M | 0 |
| Apr 18, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 27,232 | $65.10 | $1.77M | 0 |
| Apr 15, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 22,768 | $65.91 | $1.50M | 0 |
| Apr 12, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $67.79 | $16.9K | 0 |
| Apr 10, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 4,534 | $66.96 | $303.6K | 0 |
| Apr 10, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,799 | $66.96 | $187.4K | 0 |
| Apr 1, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $67.25 | $1.34M | 0 |
| Mar 23, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 6,210 | $69.58 | $432.1K | 0 |
| Mar 23, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,455 | $69.58 | $1.21M | 0 |
| Mar 23, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 3,653 | $69.58 | $254.2K | 0 |
| Mar 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $66.54 | $16.6K | 0 |
| Mar 11, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $65.81 | $1.32M | 0 |
| Mar 8, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 10,000 | $67.17 | $671.7K | 0 |
| Mar 7, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 12,003 | $65.96 | $791.7K | 0 |
| Mar 7, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,494 | $66.71 | $166.4K | 0 |
| Mar 7, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 26,372 | $66.40 | $1.75M | 0 |
| Mar 7, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,110 | $66.71 | $140.8K | 0 |
| Mar 6, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 62,317 | $66.27 | $4.13M | 0 |
| Mar 5, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,000 | $66.00 | $330.0K | 0 |
| Mar 5, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 40,000 | $65.77 | $2.63M | 0 |
| Mar 4, 2024↗ | Pera Antonio R | Director | Sell | 7,000 | $65.20 | $456.4K | 0 |
| Feb 29, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 1,914 | $67.67 | $129.5K | 0 |
| Feb 29, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,173 | $67.67 | $79.4K | 0 |
| Feb 29, 2024↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,173 | $67.67 | $79.4K | 0 |
| Feb 29, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 1,635 | $67.67 | $110.6K | 0 |
| Feb 29, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,570 | $67.67 | $106.2K | 0 |
| Feb 29, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 10,014 | $67.67 | $677.6K | 0 |
| Feb 29, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 1,058 | $67.67 | $71.6K | 0 |
| Feb 29, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,275 | $67.67 | $86.3K | 0 |
| Feb 29, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 1,122 | $67.67 | $75.9K | 0 |
| Feb 15, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,244 | $57.55 | $71.6K | 0 |
| Feb 15, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,261 | $57.55 | $72.6K | 0 |
| Feb 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.04 | $14.0K | 0 |
| Jan 19, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 25,216 | $56.17 | $1.42M | 0 |
| Jan 16, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 24,784 | $55.29 | $1.37M | 0 |
| Jan 12, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.43 | $14.1K | 0 |
| Dec 15, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $52.55 | $2.63M | 0 |
| Dec 11, 2023↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $49.21 | $12.3K | 0 |
| Nov 17, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 13,000 | $51.00 | $663.0K | 0 |
| Nov 15, 2023↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,622 | $53.81 | $141.1K | 0 |
| Nov 14, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 36,190 | $53.00 | $1.92M | 0 |
| Nov 13, 2023↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $52.03 | $13.0K | 0 |
| Nov 10, 2023↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 3,000 | $52.47 | $157.4K | 0 |
| Oct 17, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 25,000 | $57.75 | $1.44M | 0 |
| Oct 13, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 25,000 | $57.96 | $1.45M | 0 |
| Oct 2, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $56.48 | $1.13M | 0 |
| Sep 15, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $61.81 | $3.09M | 0 |
| Sep 12, 2023↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,486 | $61.91 | $92.0K | 0 |
| Sep 8, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 3,646 | $61.94 | $225.8K | 0 |
| Sep 1, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $64.70 | $1.29M | 0 |
| Aug 28, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $63.22 | $3.16M | 0 |
| Aug 23, 2023↗ | Gutwerg Ori | SVP, GENERICS | Sell | 15,561 | $62.39 | $970.9K | 0 |
| Aug 23, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 3,932 | $63.00 | $247.7K | 0 |
| Aug 14, 2023↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 17,639 | $61.37 | $1.08M | 0 |
| Aug 14, 2023↗ | Pera Antonio R | Director | Sell | 3,000 | $60.37 | $181.1K | 0 |
| Aug 14, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $61.35 | $3.07M | 0 |
| Aug 11, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 68,282 | $58.33 | $3.98M | 0 |
| Aug 1, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $51.06 | $1.02M | 0 |
| Jul 19, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 23,469 | $52.02 | $1.22M | 0 |
| Jul 18, 2023↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,743 | $51.89 | $90.4K | 0 |
| Jul 14, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 26,531 | $51.02 | $1.35M | 0 |
| Jul 3, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $53.43 | $1.07M | 0 |
| Jun 22, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $51.32 | $1.03M | 0 |
| Jun 20, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 40,000 | $51.75 | $2.07M | 0 |
| Apr 10, 2023↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 4,534 | $38.50 | $174.6K | 0 |
| Apr 10, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,289 | $38.50 | $88.1K | 0 |
| Mar 28, 2023↗ | CAREY STEPHEN P. | SVP AND CFO | Sell | 1,420 | $38.62 | $54.8K | 0 |
| Mar 28, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 524 | $38.62 | $20.2K | 0 |
| Mar 23, 2023↗ | CAREY STEPHEN P. | SVP AND CFO | Sell | 4,224 | $37.82 | $159.8K | 0 |
| Mar 23, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,455 | $37.82 | $660.1K | 0 |
| Mar 23, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,452 | $37.82 | $92.7K | 0 |
| Mar 7, 2023↗ | CAREY STEPHEN P. | SVP AND CFO | Sell | 3,503 | $44.23 | $154.9K | 0 |
| Mar 7, 2023↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,342 | $44.23 | $103.6K | 0 |
| Mar 7, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 13,662 | $44.23 | $604.3K | 0 |
| Mar 7, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,460 | $44.23 | $108.8K | 0 |
| Mar 7, 2023↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,902 | $44.23 | $84.1K | 0 |
| Feb 15, 2023↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,275 | $45.04 | $57.4K | 0 |
| Feb 15, 2023↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,292 | $45.04 | $58.2K | 0 |
| Sep 8, 2022↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 3,646 | $37.61 | $137.1K | 0 |
| Aug 12, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 18,066 | $37.26 | $673.1K | 0 |
| Apr 10, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 4,534 | $29.91 | $135.6K | 0 |
| Apr 10, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 1,878 | $29.91 | $56.2K | 0 |
| Apr 6, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 912 | $29.69 | $27.1K | 0 |
| Apr 6, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 337 | $29.69 | $10.0K | 0 |
| Mar 28, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 1,420 | $28.17 | $40.0K | 0 |
| Mar 28, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 524 | $28.17 | $14.8K | 0 |
| Mar 23, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 4,167 | $27.03 | $112.6K | 0 |
| Mar 23, 2022↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,454 | $27.03 | $471.8K | 0 |
| Mar 23, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,452 | $27.03 | $66.3K | 0 |
| Mar 21, 2022↗ | Lalwani Nikhil | PRESIDENT & CEO | Buy | 7,224 | $27.69 | $200.0K | 0 |
| Mar 21, 2022↗ | Walsh Patrick D | Director | Buy | 5,000 | $27.76 | $138.8K | 0 |
| Mar 18, 2022↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Buy | 10,000 | $27.51 | $275.1K | 0 |
| Mar 17, 2022↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Buy | 10,000 | $27.65 | $276.5K | 0 |
| Feb 15, 2022↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,167 | $40.25 | $47.0K | 0 |
| Feb 15, 2022↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,184 | $40.25 | $47.7K | 0 |
| Dec 20, 2021↗ | Thoma Jeanne | Director | Buy | 1,072 | $46.47 | $49.8K | 0 |
| Dec 7, 2021↗ | Pera Antonio R | Director | Buy | 3,000 | $42.26 | $126.8K | 0 |
| Dec 6, 2021↗ | HAUGHEY THOMAS | Director | Buy | 2,500 | $39.38 | $98.5K | 0 |
| Sep 8, 2021↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 2,577 | $28.20 | $72.7K | 0 |
| Apr 12, 2021↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 3,042 | $31.86 | $96.9K | 0 |
| Apr 12, 2021↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 1,878 | $31.86 | $59.8K | 0 |
| Apr 6, 2021↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 612 | $33.69 | $20.6K | 0 |
| Apr 6, 2021↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 337 | $33.69 | $11.4K | 0 |
| Mar 29, 2021↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 1,461 | $33.88 | $49.5K | 0 |
| Mar 29, 2021↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 802 | $33.88 | $27.2K | 0 |
| Mar 29, 2021↗ | Schrepfer Robert W | SVP - NEW BUS DEV & SPEC SALES | Sell | 5,566 | $32.68 | $181.9K | 0 |
| Mar 15, 2021↗ | Walsh Patrick D | Director | Buy | 4,000 | $32.89 | $131.6K | 0 |
ANIP Insider Buying Activity
The following table shows recent insider purchases of ANI Pharmaceuticals, Inc. (ANIP) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 21, 2022↗ | Lalwani Nikhil | PRESIDENT & CEO | Buy | 7,224 | $27.69 | $200.0K | 0 |
| Mar 21, 2022↗ | Walsh Patrick D | Director | Buy | 5,000 | $27.76 | $138.8K | 0 |
| Mar 18, 2022↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Buy | 10,000 | $27.51 | $275.1K | 0 |
| Mar 17, 2022↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Buy | 10,000 | $27.65 | $276.5K | 0 |
| Dec 20, 2021↗ | Thoma Jeanne | Director | Buy | 1,072 | $46.47 | $49.8K | 0 |
| Dec 7, 2021↗ | Pera Antonio R | Director | Buy | 3,000 | $42.26 | $126.8K | 0 |
| Dec 6, 2021↗ | HAUGHEY THOMAS | Director | Buy | 2,500 | $39.38 | $98.5K | 0 |
| Mar 15, 2021↗ | Walsh Patrick D | Director | Buy | 4,000 | $32.89 | $131.6K | 0 |
ANIP Insider Selling Activity
The following table shows recent insider sales of ANI Pharmaceuticals, Inc. (ANIP) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026↗ | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 6,572 | $74.33 | $488.5K | 57,033 |
| Mar 10, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,723 | $74.19 | $424.6K | 101,387 |
| Mar 5, 2026↗ | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 7,312 | $75.50 | $552.0K | 189,543 |
| Mar 4, 2026↗ | Gutwerg Ori | officer: SVP, GENERICS | Sell | 4,120 | $76.50 | $315.2K | 84,782 |
| Mar 4, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 834 | $74.00 | $61.7K | 103,508 |
| Mar 3, 2026↗ | Walsh Patrick D | director | Sell | 12,000 | $74.23 | $890.8K | 52,405 |
| Feb 23, 2026↗ | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 50,993 |
| Feb 23, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 84,840 |
| Feb 20, 2026↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 0 |
| Feb 19, 2026↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 0 |
| Feb 17, 2026↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,277 | $77.01 | $406.4K | 0 |
| Feb 17, 2026↗ | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $76.80 | $38.4K | 69,329 |
| Feb 17, 2026↗ | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 7,032 | $76.55 | $538.3K | 92,566 |
| Feb 12, 2026↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,813 | $77.02 | $293.7K | 0 |
| Feb 12, 2026↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,470 | $77.04 | $190.3K | 0 |
| Feb 12, 2026↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 3,325 | $77.04 | $256.2K | 0 |
| Feb 12, 2026↗ | Gutwerg Ori | SVP, GENERICS | Sell | 3,663 | $77.04 | $282.2K | 0 |
| Feb 12, 2026↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 21,986 | $77.01 | $1.69M | 0 |
| Feb 12, 2026↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 12,608 | $76.74 | $967.6K | 0 |
| Feb 12, 2026↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,051 | $77.00 | $80.9K | 0 |
| Feb 11, 2026↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,503 | $76.25 | $419.6K | 0 |
| Feb 11, 2026↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,011 | $76.25 | $229.6K | 0 |
| Feb 11, 2026↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,017 | $76.25 | $230.0K | 0 |
| Feb 11, 2026↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 4,269 | $76.25 | $325.5K | 0 |
| Feb 11, 2026↗ | Gutwerg Ori | SVP, GENERICS | Sell | 4,267 | $76.25 | $325.4K | 0 |
| Feb 11, 2026↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 30,659 | $76.25 | $2.34M | 0 |
| Feb 11, 2026↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,546 | $76.25 | $346.6K | 0 |
| Feb 11, 2026↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,762 | $76.25 | $134.4K | 0 |
| Feb 11, 2026↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,898 | $76.25 | $221.0K | 0 |
| Jan 14, 2026↗ | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 74,374 |
| Jan 13, 2026↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 0 |
| Dec 18, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,622 | $82.40 | $133.7K | 0 |
| Dec 12, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $82.32 | $32.9K | 0 |
| Dec 5, 2025↗ | TANNENBAUM RENEE P | Director | Sell | 1,800 | $81.15 | $146.1K | 0 |
| Nov 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $87.27 | $34.9K | 0 |
| Nov 13, 2025↗ | Walsh Patrick D | Director | Sell | 8,643 | $86.88 | $750.9K | 0 |
| Nov 12, 2025↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 14,736 | $89.06 | $1.31M | 0 |
| Oct 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $90.09 | $36.0K | 0 |
| Sep 19, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $98.04 | $98.0K | 0 |
| Sep 12, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $98.42 | $39.4K | 0 |
| Sep 12, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,710 | $97.71 | $167.1K | 0 |
| Sep 3, 2025↗ | Pera Antonio R | Director | Sell | 7,292 | $94.94 | $692.3K | 0 |
| Aug 25, 2025↗ | Leonard Matthew J | Director | Sell | 2,528 | $90.62 | $229.1K | 0 |
| Aug 22, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,763 | $91.10 | $160.6K | 0 |
| Aug 20, 2025↗ | Pera Antonio R | Director | Sell | 5,421 | $89.73 | $486.4K | 0 |
| Aug 20, 2025↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 100,000 | $90.36 | $9.04M | 0 |
| Aug 18, 2025↗ | Leonard Matthew J | Director | Sell | 6,937 | $88.17 | $611.6K | 0 |
| Aug 18, 2025↗ | Thoma Jeanne | Director | Sell | 21,540 | $89.15 | $1.92M | 0 |
| Aug 15, 2025↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $86.97 | $1.74M | 0 |
| Aug 15, 2025↗ | Walsh Patrick D | Director | Sell | 9,000 | $89.05 | $801.5K | 0 |
| Aug 14, 2025↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 100,000 | $88.25 | $8.82M | 0 |
| Aug 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $88.87 | $35.5K | 0 |
| Aug 12, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 50,000 | $86.07 | $4.30M | 0 |
| Aug 12, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 5,873 | $86.53 | $508.2K | 0 |
| Aug 12, 2025↗ | HAUGHEY THOMAS | Director | Sell | 19,341 | $85.93 | $1.66M | 0 |
| Aug 12, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 56,960 | $85.93 | $4.89M | 0 |
| Aug 12, 2025↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 4,975 | $85.71 | $426.4K | 0 |
| Jul 18, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 2,071 | $66.30 | $137.3K | 0 |
| Jul 14, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $64.88 | $26.0K | 0 |
| Jun 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $61.37 | $24.5K | 0 |
| May 15, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 881 | $60.07 | $52.9K | 0 |
| May 14, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,000 | $60.45 | $241.8K | 0 |
| May 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $62.20 | $24.9K | 0 |
| May 9, 2025↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 700 | $76.83 | $53.8K | 0 |
| Apr 14, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $68.96 | $27.6K | 0 |
| Mar 23, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 6,210 | $64.26 | $399.1K | 0 |
| Mar 23, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,455 | $64.26 | $1.12M | 0 |
| Mar 19, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,866 | $65.00 | $121.3K | 0 |
| Mar 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $63.33 | $25.3K | 0 |
| Mar 7, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,150 | $60.62 | $312.2K | 0 |
| Mar 7, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $60.86 | $60.9K | 0 |
| Mar 7, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 3,314 | $60.62 | $200.9K | 0 |
| Mar 7, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,060 | $60.62 | $1.03M | 0 |
| Mar 7, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,874 | $60.62 | $174.2K | 0 |
| Mar 5, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 5,384 | $60.00 | $323.0K | 0 |
| Feb 28, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 1,861 | $61.89 | $115.2K | 0 |
| Feb 28, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,099 | $61.89 | $68.0K | 0 |
| Feb 28, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,099 | $61.89 | $68.0K | 0 |
| Feb 28, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,570 | $61.89 | $97.2K | 0 |
| Feb 28, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 12,216 | $61.89 | $756.0K | 0 |
| Feb 28, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,275 | $61.89 | $78.9K | 0 |
| Feb 28, 2025↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 627 | $61.89 | $38.8K | 0 |
| Feb 21, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $60.20 | $60.2K | 0 |
| Feb 12, 2025↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 1,730 | $58.92 | $101.9K | 0 |
| Feb 12, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,834 | $59.06 | $108.3K | 0 |
| Feb 12, 2025↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,196 | $58.92 | $70.5K | 0 |
| Feb 12, 2025↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,593 | $58.92 | $152.8K | 0 |
| Feb 12, 2025↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 7,799 | $58.92 | $459.5K | 0 |
| Feb 12, 2025↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,657 | $58.92 | $156.6K | 0 |
| Feb 12, 2025↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 582 | $58.92 | $34.3K | 0 |
| Jan 13, 2025↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $53.92 | $21.6K | 0 |
| Dec 17, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 7,500 | $55.79 | $418.4K | 0 |
| Dec 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.24 | $14.1K | 0 |
| Dec 11, 2024↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $60.00 | $60.0K | 0 |
| Nov 26, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 33,481 | $57.99 | $1.94M | 0 |
| Nov 15, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 6,500 | $57.70 | $375.1K | 0 |
| Nov 15, 2024↗ | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 867 | $56.58 | $49.1K | 0 |
| Nov 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $61.36 | $15.3K | 0 |
| Oct 14, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $57.19 | $14.3K | 0 |
| Sep 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.82 | $14.2K | 0 |
| Sep 12, 2024↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,486 | $56.15 | $83.4K | 0 |
| Sep 8, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 3,646 | $60.51 | $220.6K | 0 |
| Aug 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $59.62 | $14.9K | 0 |
| Jul 18, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,743 | $61.35 | $106.9K | 0 |
| Jul 18, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,743 | $62.00 | $170.1K | 0 |
| Jul 15, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 47,257 | $63.73 | $3.01M | 0 |
| Jul 12, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $64.91 | $16.2K | 0 |
| Jul 1, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $63.44 | $1.27M | 0 |
| Jun 21, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 20,000 | $58.90 | $1.18M | 0 |
| Jun 17, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 30,000 | $60.59 | $1.82M | 0 |
| Jun 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $63.80 | $15.9K | 0 |
| Jun 7, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 11,087 | $67.70 | $750.6K | 0 |
| Jun 5, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,985 | $67.00 | $200.0K | 0 |
| Jun 4, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 5,000 | $63.58 | $317.9K | 0 |
| Jun 3, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $64.41 | $1.29M | 0 |
| May 21, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,000 | $61.61 | $123.2K | 0 |
| May 20, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 12,855 | $61.81 | $794.6K | 0 |
| May 16, 2024↗ | TANNENBAUM RENEE P | Director | Sell | 2,000 | $63.87 | $127.7K | 0 |
| May 15, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 37,145 | $64.37 | $2.39M | 0 |
| May 14, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 16,669 | $66.10 | $1.10M | 0 |
| May 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $67.69 | $16.9K | 0 |
| May 1, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $66.62 | $1.33M | 0 |
| Apr 18, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 27,232 | $65.10 | $1.77M | 0 |
| Apr 15, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 22,768 | $65.91 | $1.50M | 0 |
| Apr 12, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $67.79 | $16.9K | 0 |
| Apr 10, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 4,534 | $66.96 | $303.6K | 0 |
| Apr 10, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,799 | $66.96 | $187.4K | 0 |
| Apr 1, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $67.25 | $1.34M | 0 |
| Mar 23, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 6,210 | $69.58 | $432.1K | 0 |
| Mar 23, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,455 | $69.58 | $1.21M | 0 |
| Mar 23, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 3,653 | $69.58 | $254.2K | 0 |
| Mar 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $66.54 | $16.6K | 0 |
| Mar 11, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $65.81 | $1.32M | 0 |
| Mar 8, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 10,000 | $67.17 | $671.7K | 0 |
| Mar 7, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 12,003 | $65.96 | $791.7K | 0 |
| Mar 7, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,494 | $66.71 | $166.4K | 0 |
| Mar 7, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 26,372 | $66.40 | $1.75M | 0 |
| Mar 7, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2,110 | $66.71 | $140.8K | 0 |
| Mar 6, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 62,317 | $66.27 | $4.13M | 0 |
| Mar 5, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,000 | $66.00 | $330.0K | 0 |
| Mar 5, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 40,000 | $65.77 | $2.63M | 0 |
| Mar 4, 2024↗ | Pera Antonio R | Director | Sell | 7,000 | $65.20 | $456.4K | 0 |
| Feb 29, 2024↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 1,914 | $67.67 | $129.5K | 0 |
| Feb 29, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,173 | $67.67 | $79.4K | 0 |
| Feb 29, 2024↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,173 | $67.67 | $79.4K | 0 |
| Feb 29, 2024↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 1,635 | $67.67 | $110.6K | 0 |
| Feb 29, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,570 | $67.67 | $106.2K | 0 |
| Feb 29, 2024↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 10,014 | $67.67 | $677.6K | 0 |
| Feb 29, 2024↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 1,058 | $67.67 | $71.6K | 0 |
| Feb 29, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,275 | $67.67 | $86.3K | 0 |
| Feb 29, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 1,122 | $67.67 | $75.9K | 0 |
| Feb 15, 2024↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,244 | $57.55 | $71.6K | 0 |
| Feb 15, 2024↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,261 | $57.55 | $72.6K | 0 |
| Feb 13, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.04 | $14.0K | 0 |
| Jan 19, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 25,216 | $56.17 | $1.42M | 0 |
| Jan 16, 2024↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 24,784 | $55.29 | $1.37M | 0 |
| Jan 12, 2024↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $56.43 | $14.1K | 0 |
| Dec 15, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $52.55 | $2.63M | 0 |
| Dec 11, 2023↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $49.21 | $12.3K | 0 |
| Nov 17, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 13,000 | $51.00 | $663.0K | 0 |
| Nov 15, 2023↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,622 | $53.81 | $141.1K | 0 |
| Nov 14, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 36,190 | $53.00 | $1.92M | 0 |
| Nov 13, 2023↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 250 | $52.03 | $13.0K | 0 |
| Nov 10, 2023↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 3,000 | $52.47 | $157.4K | 0 |
| Oct 17, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 25,000 | $57.75 | $1.44M | 0 |
| Oct 13, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 25,000 | $57.96 | $1.45M | 0 |
| Oct 2, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $56.48 | $1.13M | 0 |
| Sep 15, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $61.81 | $3.09M | 0 |
| Sep 12, 2023↗ | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,486 | $61.91 | $92.0K | 0 |
| Sep 8, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 3,646 | $61.94 | $225.8K | 0 |
| Sep 1, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $64.70 | $1.29M | 0 |
| Aug 28, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $63.22 | $3.16M | 0 |
| Aug 23, 2023↗ | Gutwerg Ori | SVP, GENERICS | Sell | 15,561 | $62.39 | $970.9K | 0 |
| Aug 23, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 3,932 | $63.00 | $247.7K | 0 |
| Aug 14, 2023↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 17,639 | $61.37 | $1.08M | 0 |
| Aug 14, 2023↗ | Pera Antonio R | Director | Sell | 3,000 | $60.37 | $181.1K | 0 |
| Aug 14, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 50,000 | $61.35 | $3.07M | 0 |
| Aug 11, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 68,282 | $58.33 | $3.98M | 0 |
| Aug 1, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $51.06 | $1.02M | 0 |
| Jul 19, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 23,469 | $52.02 | $1.22M | 0 |
| Jul 18, 2023↗ | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 1,743 | $51.89 | $90.4K | 0 |
| Jul 14, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 26,531 | $51.02 | $1.35M | 0 |
| Jul 3, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $53.43 | $1.07M | 0 |
| Jun 22, 2023↗ | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 20,000 | $51.32 | $1.03M | 0 |
| Jun 20, 2023↗ | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 40,000 | $51.75 | $2.07M | 0 |
| Apr 10, 2023↗ | CAREY STEPHEN P. | SVP & CFO | Sell | 4,534 | $38.50 | $174.6K | 0 |
| Apr 10, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,289 | $38.50 | $88.1K | 0 |
| Mar 28, 2023↗ | CAREY STEPHEN P. | SVP AND CFO | Sell | 1,420 | $38.62 | $54.8K | 0 |
| Mar 28, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 524 | $38.62 | $20.2K | 0 |
| Mar 23, 2023↗ | CAREY STEPHEN P. | SVP AND CFO | Sell | 4,224 | $37.82 | $159.8K | 0 |
| Mar 23, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,455 | $37.82 | $660.1K | 0 |
| Mar 23, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,452 | $37.82 | $92.7K | 0 |
| Mar 7, 2023↗ | CAREY STEPHEN P. | SVP AND CFO | Sell | 3,503 | $44.23 | $154.9K | 0 |
| Mar 7, 2023↗ | Gutwerg Ori | SVP, GENERICS | Sell | 2,342 | $44.23 | $103.6K | 0 |
| Mar 7, 2023↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 13,662 | $44.23 | $604.3K | 0 |
| Mar 7, 2023↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,460 | $44.23 | $108.8K | 0 |
| Mar 7, 2023↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,902 | $44.23 | $84.1K | 0 |
| Feb 15, 2023↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,275 | $45.04 | $57.4K | 0 |
| Feb 15, 2023↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,292 | $45.04 | $58.2K | 0 |
| Sep 8, 2022↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 3,646 | $37.61 | $137.1K | 0 |
| Aug 12, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 18,066 | $37.26 | $673.1K | 0 |
| Apr 10, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 4,534 | $29.91 | $135.6K | 0 |
| Apr 10, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 1,878 | $29.91 | $56.2K | 0 |
| Apr 6, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 912 | $29.69 | $27.1K | 0 |
| Apr 6, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 337 | $29.69 | $10.0K | 0 |
| Mar 28, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 1,420 | $28.17 | $40.0K | 0 |
| Mar 28, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 524 | $28.17 | $14.8K | 0 |
| Mar 23, 2022↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 4,167 | $27.03 | $112.6K | 0 |
| Mar 23, 2022↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 17,454 | $27.03 | $471.8K | 0 |
| Mar 23, 2022↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 2,452 | $27.03 | $66.3K | 0 |
| Feb 15, 2022↗ | Gutwerg Ori | SVP, GENERICS | Sell | 1,167 | $40.25 | $47.0K | 0 |
| Feb 15, 2022↗ | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 1,184 | $40.25 | $47.7K | 0 |
| Sep 8, 2021↗ | Lalwani Nikhil | PRESIDENT & CEO | Sell | 2,577 | $28.20 | $72.7K | 0 |
| Apr 12, 2021↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 3,042 | $31.86 | $96.9K | 0 |
| Apr 12, 2021↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 1,878 | $31.86 | $59.8K | 0 |
| Apr 6, 2021↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 612 | $33.69 | $20.6K | 0 |
| Apr 6, 2021↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 337 | $33.69 | $11.4K | 0 |
| Mar 29, 2021↗ | CAREY STEPHEN P. | SENIOR VICE PRESIDENT AND CFO | Sell | 1,461 | $33.88 | $49.5K | 0 |
| Mar 29, 2021↗ | Marken James G. | SVP OPS & PROD DEV | Sell | 802 | $33.88 | $27.2K | 0 |
| Mar 29, 2021↗ | Schrepfer Robert W | SVP - NEW BUS DEV & SPEC SALES | Sell | 5,566 | $32.68 | $181.9K | 0 |
ANIP Insiders
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
Bought $276.5KSold $59.00M
64 tradesLast: Feb 11, 2026
Similar Stocks to ANIP
ZTS
Zoetis Inc.
$115.50+0.03%
$50.88B
TEVA
Teva Pharmaceutical Industries Limited
$28.41-3.04%
$36.69B
VTRS
Viatris Inc.
$13.53-1.99%
$18.79B
NBIX
Neurocrine Biosciences, Inc.
$129.43+1.29%
$13.13B
INDV
Indivior Pharmaceuticals Inc
$31.32+1.49%
$4.05B
SUPN
Supernus Pharmaceuticals, Inc.
$49.80-1.30%
$3.08B
PAHC
Phibro Animal Health Corporation
$49.52+1.06%
$1.95B
PRGO
Perrigo Company plc
$9.23-1.96%
$1.39B